190 related articles for article (PubMed ID: 32191246)
21. Efficient "green" encapsulation of a highly hydrophilic anticancer drug in metal-organic framework nanoparticles.
Rodriguez-Ruiz V; Maksimenko A; Anand R; Monti S; Agostoni V; Couvreur P; Lampropoulou M; Yannakopoulou K; Gref R
J Drug Target; 2015; 23(7-8):759-67. PubMed ID: 26453171
[TBL] [Abstract][Full Text] [Related]
22. Polymer Coated Iron Nanoparticles: Radiolabeling & In vitro Studies.
Yilmaz S; Ichedef C; Karatay KB; Teksöz S
Curr Radiopharm; 2021; 14(1):37-45. PubMed ID: 32351192
[TBL] [Abstract][Full Text] [Related]
23. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
24. Macromolecular bipill of gemcitabine and methotrexate facilitates tumor-specific dual drug therapy with higher benefit-to-risk ratio.
Das M; Jain R; Agrawal AK; Thanki K; Jain S
Bioconjug Chem; 2014 Mar; 25(3):501-9. PubMed ID: 24506698
[TBL] [Abstract][Full Text] [Related]
25. Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats.
Karuppaiah A; Babu D; Selvaraj D; Natrajan T; Rajan R; Gautam M; Ranganathan H; Siram K; Nesamony J; Sankar V
Eur J Pharm Sci; 2021 Oct; 165():105938. PubMed ID: 34256103
[TBL] [Abstract][Full Text] [Related]
26. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
27. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
28. BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs.
Chitkara D; Kumar N
Pharm Res; 2013 Sep; 30(9):2396-409. PubMed ID: 23756758
[TBL] [Abstract][Full Text] [Related]
29. pH and singlet oxygen dual-responsive GEM prodrug micelles for efficient combination therapy of chemotherapy and photodynamic therapy.
Chen L; Zhuang W; Hu C; Yu T; Su X; Liang Z; Li G; Wang Y
J Mater Chem B; 2020 Jul; 8(26):5645-5654. PubMed ID: 32538389
[TBL] [Abstract][Full Text] [Related]
30. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.
Yu X; Di Y; Xie C; Song Y; He H; Li H; Pu X; Lu W; Fu D; Jin C
Int J Nanomedicine; 2015; 10():6825-34. PubMed ID: 26586944
[TBL] [Abstract][Full Text] [Related]
31. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
32. Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows
Liu D; Zhang W; Liu X; Qiu R
Drug Deliv; 2021 Dec; 28(1):776-786. PubMed ID: 33866910
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Tang Z; Feng W; Yang Y; Wang Q
Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
[TBL] [Abstract][Full Text] [Related]
34. Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug.
Parsian M; Unsoy G; Mutlu P; Yalcin S; Tezcaner A; Gunduz U
Eur J Pharmacol; 2016 Aug; 784():121-8. PubMed ID: 27181067
[TBL] [Abstract][Full Text] [Related]
35. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
36. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy.
Sun J; Chen Y; Xu J; Song X; Wan Z; Du Y; Ma W; Li X; Zhang L; Li S
Theranostics; 2020; 10(3):1136-1150. PubMed ID: 31938056
[TBL] [Abstract][Full Text] [Related]
37. In vivo drug delivery of gemcitabine with PEGylated single-walled carbon nanotubes.
Razzazan A; Atyabi F; Kazemi B; Dinarvand R
Mater Sci Eng C Mater Biol Appl; 2016 May; 62():614-25. PubMed ID: 26952465
[TBL] [Abstract][Full Text] [Related]
38. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
39. Design and fabrication of dual-targeted delivery system based on gemcitabine-conjugated human serum albumin nanoparticles.
Norouzi P; Amini M; Mottaghitalab F; Mirzazadeh Tekie FS; Dinarvand R; Mirzaie ZH; Atyabi F
Chem Biol Drug Des; 2020 Aug; 96(2):745-757. PubMed ID: 28640541
[TBL] [Abstract][Full Text] [Related]
40. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
